RU2005114573A -
METHOD FOR COUPLING ABSTINENT SYNDROME IN OPIEN DRUG PATIENTS
- Google Patents
METHOD FOR COUPLING ABSTINENT SYNDROME IN OPIEN DRUG PATIENTS
Download PDF
Info
Publication number
RU2005114573A
RU2005114573ARU2005114573/14ARU2005114573ARU2005114573ARU 2005114573 ARU2005114573 ARU 2005114573ARU 2005114573/14 ARU2005114573/14 ARU 2005114573/14ARU 2005114573 ARU2005114573 ARU 2005114573ARU 2005114573 ARU2005114573 ARU 2005114573A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Евгений Евгеньевич Щерба (RU), Евгений Евгеньевич ЩербаfiledCriticalЕвгений Евгеньевич Щерба (RU)
Priority to RU2005114573/14ApriorityCriticalpatent/RU2290955C1/en
Publication of RU2005114573ApublicationCriticalpatent/RU2005114573A/en
Application grantedgrantedCritical
Publication of RU2290955C1publicationCriticalpatent/RU2290955C1/en
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Claims (1)
Способ купирования абстинентного синдрома у больных опийной наркоманией, включающий воздействие на его организм стрессорным фактором, отличающийся тем, что в качестве стрессорного фактора используют острую массивную кровопотерю в объеме от 10 до 20% от общего объема крови в зависимости от длительности употребления и суточной дозы наркотика.A method of relieving withdrawal symptoms in patients with opiate addiction, including exposure to his body as a stress factor, characterized in that acute massive blood loss in the amount of 10 to 20% of the total blood volume depending on the duration of use and the daily dose of the drug is used as a stress factor.
RU2005114573/14A2005-05-132005-05-13Method for interrupting abstinence syndrome in patients at opium narcomania
RU2290955C1
(en)
Injectable preparation containing diclofenic, a process for its preparation and use of the preparation in the manufacture of medication for the relief of pain and/or inflammation
New use of selective serotonin reuptake inhibitors for treatment of human patients with chest pain of non-cardiac origin or with gastro-esophageal reflux disease